Successful Partnering Models for Pharma and Biotech Companies To Be A Major Theme at `Sachs-Bloomberg Global Biotech Forum for Investing & Partnering', March 20-21, Fairmont Copley, Boston.Business Editors/Health/Medical Writers Sachs Global Biotech bi·o·tech n. Informal Biotechnology. biotech Noun short for biotechnology Noun 1. Investor Forum 2003 BOSTON--(BUSINESS WIRE)--March 10, 2003 "BioPartnering" panel to be moderated by Eileen Smith Ewing, Esq., Partner & Chair, Life Sciences Practice Group, Kirkpatrick & Lockhart "BioPartnering" panelists will include: Margaret A. Flanagan, PhD, Global Alliance Director, Enabling Science & Technology, AstraZeneca Pharmaceuticals; Samir Master, MD, VP/Business Development & Licensing, Global Head, Search & Evaluation, Novartis Pharma AG; and Jan van Heek, EVP EVP Executive Vice President EVP EGR (Exhaust Gas Recirculation) Valve Position Sensor EVP Electronic Voice Phenomenon EVP Europäische Volkspartei (Germany) EVP Employee Value Proposition , Therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. & Genetics genetics, scientific study of the mechanism of heredity. While Gregor Mendel first presented his findings on the statistical laws governing the transmission of certain traits from generation to generation in 1856, it was not until the discovery and detailed study of , Genzyme Corporation Sachs Associates announced today that its annual Sachs-Bloomberg Global Biotech Forum for Investing & Partnering will be held on March 20-21, 2003, at the Fairmont Copley Plaza The Fairmont Copley Plaza hotel (or Copley Plaza as it is colloquially known) is a four-star hotel in downtown Boston, Massachusetts. It was built in 1912 on St. James Avenue and defines the south side of Copley Square. The Copley Plaza Hotel opened in 1912. in Boston. This international meeting draws together a cross-section of venture-funded and small-cap companies with leading investors and pharmaceutical companies. The event is expected to attract an audience of more than 400 investors and business-development executives, and 59 presenting companies. The Boston program will look jointly at issues of BioPartnering and BioInvesting. For more information about this event, visit www.sachsforum.com. "Very few business deals are as risky as a product development alliance with a biotech company," said Eileen Smith Ewing, Esq., Partner and Chair of the Life Sciences Practice Group at Kirkpatrick & Lockhart LLP LLP - Lower Layer Protocol , Boston. "Consider how few of these products reach commercialization, despite the dollars and years expended ex·pend tr.v. ex·pend·ed, ex·pend·ing, ex·pends 1. To lay out; spend: expending tax revenues on government operations. See Synonyms at spend. 2. . "And when a pharmaceutical company finally brings a drug to market, its peers may be close behind with competing products," added Ewing. "It's understandable that big pharma constructs these deals to minimize downstream risk - and that little biotech, by contrast, tries to maximize its own share in the future upside Upside The potential dollar amount by which the market or a stock could rise. Notes: This is basically an educated guess on how high a stock could go in the near future. See also: Bull, Downside , proportional to its early concessions to its partner." "At least pharma is willing to take these risks early in the game. Venture capital partners have become more reluctant to invest before clinical trials have begun," said Ewing, who will moderate a "BioPartnering" panel discussion at the Sachs-Bloomberg Global Biotech Forum for Investing & Partnering. Ms. Ewing's panel of experts will include: Dr. Margaret A. Flanagan, AstraZeneca Pharmaceuticals; Dr. Samir Master, Novartis Pharma AG; and, Jan van Heek, Genzyme Corporation. To register for the conference, contact Ms. Pernilla Hellsten at Pernilla@sachsforum.com. Since 1997, Sachs Associates, a London-based company that organizes and produces securities markets conferences, has been working in collaboration with Bloomberg LP, the fastest-growing electronic real-time financial information provider. Business Wire is the official news service for the Sachs-Bloomberg Global Biotech Forum for Investing & Partnering. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion